利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17664 条记录 (耗时 0.041 秒)

    Methods for Treatment of Alport Syndrome
    36.
    发明公开
    Methods for Treatment of Alport Syndrome 审中-公开

    公开(公告)号：US20240115598A1

    公开(公告)日：2024-04-11

    申请号：US18446743

    申请日：2023-08-09

    申请人： Sanofi

    发明人： Timothy Wright

    IPC分类号： A61K31/712 ,  A61K9/00 ,  A61K48/00 ,  A61P13/12 ,  C12N15/113

    CPC分类号： A61K31/712 ,  A61K9/0019 ,  A61K48/00 ,  A61P13/12 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/141

    摘要： Provided herein are methods for the treatment of Alport syndrome, using a modified oligonucleotide targeted to miR-21. In certain embodiments, the modified oligonucleotide targeted to miR-21 improves kidney function and/or reduces fibrosis in subjects having Alport syndrome. In certain embodiments, administration of the modified oligonucleotide targeted to miR-21 delays the onset of end-stage renal disease in a subject having Alport syndrome. In certain embodiments, the modified oligonucleotide targeted to miR-21 delays the need for dialysis or kidney transplant in a subject having Alport syndrome.

    STABLE TARGET-EDITING GUIDE RNA TO WHICH CHEMICALLY MODIFIED NUCLEIC ACID IS INTRODUCED
    38.
    发明公开
    STABLE TARGET-EDITING GUIDE RNA TO WHICH CHEMICALLY MODIFIED NUCLEIC ACID IS INTRODUCED 审中-公开

    公开(公告)号：US20240093227A1

    公开(公告)日：2024-03-21

    申请号：US18265756

    申请日：2021-12-08

    申请人： FUKUOKA UNIVERSITY ,  DAIICHI SANKYO COMPANY, LIMITED

    发明人： Masatora FUKUDA ,  Makoto KOIZUMI ,  Shinzo IWASHITA

    IPC分类号： C12N15/85 ,  C12N9/78 ,  C12N15/11

    CPC分类号： C12N15/85 ,  C12N9/78 ,  C12N15/11 ,  C12Y305/04 ,  A61K48/00 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2800/107

    摘要： Provided is an oligonucleotide which may induce an editing activity of ADRC in cell and has excellent stability in a living body. The oligonucleotide includes a first oligonucleotide identifying a target RNA and a second oligonucleotide linked to the 5′-side of the first oligonucleotide. The first oligonucleotide consists of a target-corresponding nucleotide residue, an oligonucleotide of 10 to 24 residues at the 3′-side, and an oligonucleotide of 3 to 6 residues at the 5′-side. The second oligonucleotide has no nucleotide residue corresponding to a nucleotide residue of the target RNA or has a nucleotide residue which does not form a complementary pair at the 3′-end thereof and the number of residue is 3 to 6. The residue at the 3′-side of the target-corresponding nucleotide residue is a 2′-deoxynucleotide residue, and the third nucleotide residue counted in the 3′-direction from the target-corresponding nucleotide in the oligonucleotide at the 3′-side of the target-corresponding nucleotide residue is a 2′-deoxy-2′-fluoronucleotide residue.